Financial Data and Key Metrics Changes - In Q4 2025, the company recognized $6.2 million in total net revenue, with $5.4 million from the U.S. commercial launch of PALSONIFY and $0.8 million from a licensing agreement with SKK [24] - Total revenue for the full year 2025 was $7.7 million, with a cost of product revenue of $1.1 million in Q4 [24][25] - Research and development expenses for Q4 were $85.1 million, down from $90.5 million in Q3, while selling, general, and administrative expenses were $53.7 million, relatively stable compared to $52.3 million in Q3 [25] - The company ended 2025 with over $1 billion in cash equivalents and investments, which does not include $380 million from a public offering in January 2026 [26] Business Line Data and Key Metrics Changes - The launch of PALSONIFY has seen over 200 enrollment forms in Q4, with more than 125 unique prescribers involved [6][7] - The company is focusing on building a fully integrated commercial enterprise to support PALSONIFY, including sales professionals and patient support services [8][9] Market Data and Key Metrics Changes - The company is experiencing encouraging formulary momentum with payers, securing wins with top plans in the U.S. for PALSONIFY [7] - Approximately 50% of patients are reimbursed for commercial or government payers, while the other 50% are utilizing the QuickStart program [48][62] Company Strategy and Development Direction - The company is transitioning from building a pipeline to building a business, aiming to establish PALSONIFY as the new standard of care for acromegaly [5][10] - The focus is on expanding the commercial business and advancing clinical trials for other pipeline candidates, including atumelnant for CAH and Cushing's disease [10][30] - The company received a positive CHMP opinion for PALSONIFY in the EU, reflecting the strength of their data [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, highlighting simultaneous execution across the portfolio and ongoing advancements in clinical trials [30] - The company believes existing cash and investments will be sufficient to fund operations into 2030, providing a significant runway for commercialization and clinical development [27] Other Important Information - The company is committed to transforming the lives of people with endocrine diseases and creating long-term sustainable value for stakeholders [30] - The EQUILIBRIUM ADCS study is designed to assess the safety and efficacy of atumelnant in treating ADCS, with a seamless transition from phase 2 to phase 3 [20][23] Q&A Session Summary Question: Insights from Phase 2/3 design and learnings from other studies - Management noted that the structure of the Cushing's disease study is well precedented, with normalization of urine-free cortisol as a primary endpoint [34][66] Question: Trends in PALSONIFY prescriptions - Management is pleased with the launch and early positive experiences from prescribers and patients, but refrained from providing quantitative comments on trends [40][43] Question: Enrollment forms and commercial therapy timeline - Management indicated that it is premature to extrapolate the 200 enrollment forms but expressed satisfaction with the number [47] Question: Payer dynamics for PALSONIFY - Management reported positive progress in market access with no significant barriers to treatment, and most coverage is based on the product's label [62] Question: Phase 3 endpoints for ADCS study - The primary endpoint for phase 3 is set by the FDA, focusing on the percentage of patients achieving normal urine-free cortisol [66]